Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) Accounts Payable

As of the most recent data (June 2026), RVPHW shows a accounts payable of $2.5T. That compares with $5M in the prior-year period — up 49432506.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RVPHW's accounts payable is now $2.5T (was $5M) — a 49432506.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) is outperforming or lagging.

Tracking RVPHW's accounts payable over time shows whether Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $2.5T That compares with $5M in the prior-year period — up 49432506.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.5T) with ownership activity and broader fundamentals.

Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s accounts payable is $2.5T; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.